The short-term benefits (i.e., to 3 months) of variable types and dosages of exercise were demonstrated for a number
of outcomes including pain, stiffness, function, balance, biomarkers, and executive function and dual task performance (related to falling) in people with knee OA. Modalities such as 890-nm radiation, interferential current, short wave diathermy, ultrasound and neuromuscular functional electrical stimulation did not demonstrate benefit over sham controls in those with knee OA. Spa therapy improved pain over the period of treatment in those with knee and hand OA. Supervised self-management based on cognitive therapy principles resulted in improved outcomes PFTα for people with knee OA. Shock absorbing insoles compared to
normal footwear minimally improved knee pain and but not function and did not decrease knee load. Neuromuscular and motor training improved function in those with total hip replacement. Accelerated weight-bearing and rehabilitation (8 versus 11 weeks) was demonstrated to be safe and effective SNX-5422 concentration at 5 years following matrix autologous chondrocyte implantation for cartilage defects in the knee.
Conclusions: Exercise remains a mainstay of conservative management although most studies report only short-term outcomes. Self-management strategies also are beneficial in knee OA. There seems to be a placebo effect with most trials of physical modalities although spa therapy demonstrated very short-term effects. (C) 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.”
“It is recommended that attention be CP-868596 given to the shelf life of botulinum toxin type A (BT-A) after its reconstitution.
To assess the efficacy and safety of 500 U of BT-A after reconstitution up to 15 days after injection.
BT-A vials were diluted 15 days, 8 days, and 8 hours before injection. One hundred five volunteers were randomized to one of three treatment groups, according to dilution dates. They were evaluated at baseline and 28, 56, 84, and 112 days after treatment. At each visit, the investigator
and the volunteer evaluated the motility of the treated area using a 4-point qualitative scale. Five independent specialists, who scored the motility of the treated area on the same scale, blind analyzed photographs taken at each visit. The reconstituted vials of BT-A were stored and analyzed before and after the study.
No significant difference was shown between the groups. No evidence of contamination was found in the BT-A vials.
The results confirm the possibility of injecting 500 U of BT-A up to 15 days after its reconstitution safely and without loss of efficacy.
This study was supported by the Brazilian Center for Studies in Dermatology, a nonprofit organization. The Brazilian Center for Studies in Dermatology received an educational grant from Ipsen, Inc (the manufacturer of Dysport/Reloxin). Dr. Hexsel is a researcher, consultant, and stockholder of Ipsen, Inc.